PCI Clinical Services has appointed Lisa Spence as Director of Clinical Supply Chain, International Region.
 
Based out of the UK, Lisa will partner with Katy Ostertag-Johnson, director of clinical supply chain, North America, to build and lead the expansion of PCI’s SMART Supply Management team, providing a harmonized global service offering for clients executing global studies in both domestic and emerging market geographies.
 
PCI’s SMART team directly supports clients in clinical study design and execution, facilitating smooth and efficient clinical trial supply strategies including forecasting of clinical supply demand, building drug projections, dynamic inventory management and overseeing tailored packaging, labeling and distribution models. The team leverages expertise in factors such as assessing clinical protocol revisions and analyze enrollment rates, usage, and trends to benefit clients. In this new role at PCI, Lisa brings significant logistics, operations, regulatory and clinical supply experience, having previously held senior positions at sponsor companies including MedImmune, Pfizer, GSK, and Merck.
 
“Lisa is highly talented, and we are delighted to welcome her to PCI,” said Brian Keesee, vice president and general manager, global clinical operations and supply. “With her considerable experience in logistics and operations for global clinical studies, she will be instrumental in providing our clients with invaluable insights and best practices for executing studies more quickly and effectively. Studies are increasingly complex, with multi-country administration, factors such as cold chain or ultra cold chain requirements, as well as new advancing logistical models. Lisa is a great fit for our mission to deliver the industry-leading customer experience for PCI’s clients across the world, helping them advance new therapies to realize successful outcomes.”
  
PCI’s UK location recently completed significant facilities expansion, opening a new state-of-the-art building for logistical activities, investment in an additional dedicated drug product returns facility, as well as expansion of its cold chain infrastructure.